Couple things here, this is retinoic acid metabolism btw.
Retinaldehyde dehydrogenase 2 as a molecular adjuvant for enhancement of mucosal immunity during DNA vaccination
RALDH2 can be used as an alternative adjuvant to ATRA during DNA vaccination leading to an increase in both systemic and mucosal T cell immunity and better protection at mucosal sites.
Dendritic cells (DCs) from the gut-associated lymphoid organs produce RA and imprint T cells with gut-homing potential [14, 21]. The administration of ATRA, the major metabolic derivative of vitamin A, has been shown to act physiologically to induce expression of gut-homing receptors on lymphocytes [11]. Unfortunately, ATRA is practically insoluble in water, which precludes its inclusion in many vaccines [22].
In this study we are transfecting epithelial cells with a RALDH2 DNA construct using an intramuscular-electroporation regime with the final objective of increasing mucosal-homing T cells and protection against viral challenge. We hypothesized that RA produced by transfected muscle epithelial cells could imprint DCs that traffic to the site of immunization with a mucosal phenotype (i.e. the ability to produce RA themselves). Alternatively, transfected DCs can be conditioned to produce RA and present the vaccine antigen in draining lymph nodes, the RA they produce should then instruct the responding lymphocytes to migrate to mucosal tissues.
Our results demonstrate that RALDH2 immunization increases systemic responses and protects from future mucosal viral challenge. A similar effect has been previously observed when ATRA is used as an adjuvant